Key Details
Annual Revenue
$177.13 MAnnual EPS
-$1.44Annual ROE
-35.39%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 08, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Screeners with SILK included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Similar stocks
MARLBOROUGH, Mass. , Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that pioneered a new approach for stroke prevention and the treatment of carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR).
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Silk Road Medical, Inc. ( N asdaq : SILK ) , relating to its proposed merger with Boston Scientific Corporation and Seminole Merger Sub. Under the terms of the agreement, Silk Road stockholders will receive $27.50 in cash for each share they own.
NEW YORK , Aug. 20, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Silk Road Medical, Inc. (Nasdaq: SILK ), relating to its proposed merger with Boston Scientific Corporation and Seminole Merger Sub.
MONSEY, N.Y., Aug. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP has renewed its investigation into the fairness of the proposed sale of Silk Road Medical, Inc. (Nasdaq: SILK) (“SILK”) to Boston Scientific Corporation for $27.50 per share in cash.
Silk Road Medical (SILK) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.35 per share a year ago.
Studied across thousands of patients and supported by hundreds of clinical publications, the TCAR pioneer has continually delivered positive outcomes through minimally invasive techniques
NEW YORK , July 29, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Silk Road Medical, Inc. (Nasdaq: SILK ), relating to its proposed merger with Boston Scientific Corporation and Seminole Merger Sub.
NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Silk Road Medical, Inc. ( N asdaq : SILK ) , relating to its proposed merger with Boston Scientific Corporation and Seminole Merger Sub. Under the terms of the agreement, Silk Road stockholders will receive $27.50 in cash for each share they own.
MONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $27.50 per share in cash for which Silk Road Medical, Inc. (Nasdaq: SILK) (“SILK”) has agreed to be sold to Boston Scientific Corporation (“Boston Scientific”).
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Silk Road Medical, Inc. (NasdaqGS: SILK) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Silk Road will receive $27.50 in cash for each share of Silk Road that they own. KSF is seeking to determine whether this consideration and the process that led to.
FAQ
- What is the primary business of Silk Road Medical?
- What is the ticker symbol for Silk Road Medical?
- Does Silk Road Medical pay dividends?
- What sector is Silk Road Medical in?
- What industry is Silk Road Medical in?
- What country is Silk Road Medical based in?
- When did Silk Road Medical go public?
- Is Silk Road Medical in the S&P 500?
- Is Silk Road Medical in the NASDAQ 100?
- Is Silk Road Medical in the Dow Jones?
- When was Silk Road Medical's last earnings report?
- When does Silk Road Medical report earnings?
- Should I buy Silk Road Medical stock now?